- Home
- ASMB vs CPHC Comparison
ASMB vs CPHC Comparison
Compare ASMB & CPHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- CPHC
- Stock Information
- Founded
- ASMB 2005
- CPHC 1994
- Country
- ASMB United States
- CPHC United States
- Employees
- ASMB N/A
- CPHC N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- CPHC Services-Misc. Amusement & Recreation
- Sector
- ASMB Health Care
- CPHC Consumer Discretionary
- Exchange
- ASMB Nasdaq
- CPHC Nasdaq
- Market Cap
- ASMB 84.5M
- CPHC 85.7M
- IPO Year
- ASMB 2010
- CPHC 1994
- Fundamental
- Price
- ASMB $10.03
- CPHC $17.20
- Analyst Decision
- ASMB Strong Buy
- CPHC
- Analyst Count
- ASMB 3
- CPHC 0
- Target Price
- ASMB $33.00
- CPHC N/A
- AVG Volume (30 Days)
- ASMB 37.9K
- CPHC 1.1K
- Earning Date
- ASMB 05-07-2025
- CPHC 05-08-2025
- Dividend Yield
- ASMB N/A
- CPHC 1.63%
- EPS Growth
- ASMB N/A
- CPHC N/A
- EPS
- ASMB N/A
- CPHC 0.42
- Revenue
- ASMB $28,520,000.00
- CPHC $61,562,288.00
- Revenue This Year
- ASMB $10.82
- CPHC N/A
- Revenue Next Year
- ASMB N/A
- CPHC N/A
- P/E Ratio
- ASMB N/A
- CPHC $40.95
- Revenue Growth
- ASMB 298.16
- CPHC 0.20
- 52 Week Low
- ASMB $7.75
- CPHC $17.00
- 52 Week High
- ASMB $19.93
- CPHC $24.78
- Technical
- Relative Strength Index (RSI)
- ASMB 48.99
- CPHC 29.47
- Support Level
- ASMB $7.90
- CPHC $17.00
- Resistance Level
- ASMB $10.36
- CPHC $17.47
- Average True Range (ATR)
- ASMB 0.85
- CPHC 0.11
- MACD
- ASMB 0.21
- CPHC -0.02
- Stochastic Oscillator
- ASMB 86.04
- CPHC 13.33
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About CPHC Canterbury Park Holding Corporation 'New'
Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.